On 15 June 2015, Prosonix was acquired by Circassia Pharmaceuticals plc creating a world-class allergy and asthma specialty biopharma business .
For more information on Circassia, please go to
May 15, 2015
Prosonix enters Definitive Agreement to be acquired by Circassia Pharmaceuticals plc for up to £100 million in Cash
Sep 11, 2014
Prosonix Confirms the Potential of its Multi-Component Particle™ Technology for Developing Novel Inhaled Dual...
Sep 2, 2014
Prosonix’ Marketing Authorisation Application for PSX1001 – a Generic Version of GlaxoSmithKline’s Flixotide®...
Terms & Conditions
© Prosonix Ltd, 2016
The Medawar Centre Robert Robinson Avenue Oxford Science Park Oxford OX4 4GA United Kingdom | Tel: +44 (0)1865 784250 | Email: